SINTX TECHNOLOGIES INC

Discover how Sintx Technologies uses silicon nitride to pioneer spinal fusion and joint‑replacement devices, balancing growth, volatility, and U.S. market focus.

Discover how Sintx Technologies leverages silicon nitride to create durable, biocompatible spinal, hip, and knee implants that improve patient outcomes in the U.S. healthcare market.

SiNtx Technologies Inc.: Small‑cap biomaterial medical devices, $9.89 M market cap, negative P/E, growth‑stage focus on silicon‑nitride spinal and joint implants—track FDA approvals and earnings for upside.

SiNtx Technologies

SiNtx Technologies launches OsseoSculpt, a silicon‑nitride bone‑healing biologic for its SINAPTIC ankle system, while securing a private‑label deal to expand market reach.

SiNtx Technologies Inc. has published a groundbreaking study demonstrating the broad-spectrum antiviral activity of its silicon nitride technology against coronaviruses, leading to a significant increase in the company’s stock price.

SiNtx Technologies Inc. is struggling financially and faces an uncertain future in the competitive health care sector, with a negative earnings outlook and a declining stock price.

SiNtx Technologies Inc. has reported a decline in stock price, with a recent close of $3.3082, amidst financial challenges and a negative price-to-earnings ratio, despite its innovative approach in the health care sector.